Richard Baldry

4PUBLICATIONS
58CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursFoetal development and medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jan 27, 2026
Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

Susanne A Gatz, Pablo Berlanga, Gwénaël Le Teuff

|Jul 10, 2025
Population Pharmacokinetics and Exposure-Response Analysis of First-Line Osimertinib Plus Chemotherapy in Patients with EGFR-Mutated Advanced NSCLC.

Jincheng Yang, Damilola Olabode, Aarti Sawant-Basak

|Jun 03, 2024
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).

Sehhoon Park, Richard Baldry, Hyun Ae Jung

|Apr 30, 2024
Zibotentan Can Be Co-administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug-Drug Interaction Study.

Anne-Kristina Mercier, Abigail K Kois, Deeyen Karsanji

Pageof 1

Frequent Collaborators

1 joint publications

Anne-Kristina Mercier

1 joint publications

Deeyen Karsanji

1 joint publications

Filip Birve

1 joint publications

Oleksandr Molodetskyi